MRK  Merck & Company Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-1.02 (-1.67%)

Growth Price

Overvalued by 9.18%

Stability Price

Overvalued by 65.77%

Company Metrics

  • P/E 30.72
  • P/S 4.23
  • P/B 3.86
  • EPS 1.96
  • Cash ROIC 12.97%
  • Cash Ratio 0.70
  • Dividend 1.88 / 3.06%
  • Avg. Vol. 11.12M
  • Shares 2.76B
  • Market Cap. 165.84B

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


2 Big Reasons Merck & Co., Inc. Stock Surged 11% in 2016
Motley Fool - Jan 6, 2017
Shares of Merck & Co., Inc. (NYSE:MRK), a U.S.-based global drug behemoth, climbed 11% higher in 2016, according to data from S&P Global Market Intelligence, slightly outpacing the 9.5% return of the S&P 500, and putting the SPDR S&P Pharmaceuticals ...
Merck & Company Inc. (new) (MRK) Closes 1.37% Down on the Day for January 19 - 13 hours ago
Shares of Merck & Company Inc. (new) (MRK) ended the trading day Thursday at $60.33, representing a move of -1.37%, or $0.84 per share, on volume of 11.25 million shares.
Analysts Advise About Merck & Co., Inc. (NYSE:MRK) - The Independent Republic
The Coconut Grove Bank Has $1797000 Stake in Merck & Company, Inc. (MRK) - DailyQuint
Merck & Co., Inc. (NYSE:MRK): Upgraded To Overweight
Smаrt Stоck Nеws - Jan 13, 2017
Merck & Co., Inc. (NYSE:MRK) issued an update highlighting that FDA had accepted a filing based on the KEYNOTE 021G data presented at ESMO comparing Keytruda + chemo vs chemo alone in all PD-L1 sub-groups.
Merck Muscles Into Bristol's Combo Space - Seeking Alpha
US FDA agrees to accelerated review of Merck immunotherapy drug combination ... - Proactive Investors USA & Canada
Most Recent analysts Ratings: Merck & Co., Inc. (NYSE:MRK)
News Oracle - Jan 13, 2017
Some buy side analysts are also providing their Analysis on Merck & Co., Inc., where 2 analysts have rated the stock as Strong buy, 8 analysts have given a Buy signal, 11 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as ...
Merck & Company Inc. (new) (MRK) Closes 0.21% Up on the Day for January 16 -
Merck & Company, Inc. (MRK) Rating Increased to Buy at Guggenheim - Sports Perspectives
What do Analysts suggest for: Merck & Co., Inc. (NYSE:MRK)
News Oracle - Jan 9, 2017
Merck & Co., Inc. (NYSE:MRK) will report its next earnings on 2-Feb-17. The company reported the earnings of $1.07/Share in the last quarter where the estimated EPS by analysts was $0.99/share.
Stock's Stunning Activities: Merck & Co., Inc. (NYSE:MRK) - FactsReporter
Merck & Company Inc. (new) (MRK) Rises 2.85% for January 11 -
Merck & Co., Inc. (MRK) Stock Is Defying the Bears! - Jan 4, 2017
The first trading day of 2017 was a mixed session. Although the broader indices ended higher on the day, underneath the surface, things traded in a sloppy fashion.
analysts Recommendations: Merck & Co., Inc. (NYSE:MRK) - News Oracle
Merck & Company Inc. (new) (MRK) Closes 0.03% Down on the Day for January 05 -
News Review: Merck & Co., Inc. (NYSE:MRK), Comcast Corporation (NASDAQ:CMCSA)
FactsReporter - Jan 18, 2017
The company announced its last quarter financial performance results on 10/25/2016. Merck & Co., Inc. (NYSE:MRK) belongs to Medical sector that declined -1.38% in value when last trading session closed at $61.48.
Traders Watch list: Merck & Co., Inc. (MRK), Comcast Corporation (CMCSA ... - iStreetWire
Merck & Co., Inc. (NYSE:MRK) Joins Forces With M2Gen To Explore The ORIEN ...
Market Exclusive - Jan 6, 2017
Merck & Co., Inc. (NYSE:MRK), which is popularly known as MSD outside the United States and Canada, has become part of the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program.
Analysts' Recommendations Trending Stocks: Merck & Co., Inc. (NYSE:MRK ... - Money News
Active Stock Momentum: Merck & Co., Inc. (NYSE:MRK)
FactsReporter - Dec 30, 2016
Many analysts have provided their estimated foresights on Merck & Co., Inc. Earnings, with 17 analysts believing the company would generate an Average Estimate of $0.88.
Merck & Company Inc. (new) (MRK) Closes 0.87% Down on the Day for December 28 -
Merck, IBM Pace DJIA to Wednesday Gain
24/7 Wall St. - Jan 11, 2017
The DJIA stock posting the largest daily percentage gain ahead of the close Wednesday was Merck & Co. Inc. (NYSE: MRK) which traded up about 2.65% at $61.51.